These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28150354)

  • 21. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
    Solár P; Sytkowski AJ
    Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.
    Chen LY; Huang RL; Chan MW; Yan PS; Huang TS; Wu RC; Suryo Rahmanto Y; Su PH; Weng YC; Chou JL; Chao TK; Wang YC; Shih IM; Lai HC
    J Pathol; 2019 Jul; 248(3):363-376. PubMed ID: 30883733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.
    Zheng ZG; Xu H; Suo SS; Xu XL; Ni MW; Gu LH; Chen W; Wang LY; Zhao Y; Tian B; Hua YJ
    Sci Rep; 2016 May; 6():26093. PubMed ID: 27193186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
    Gong TT; Liu XD; Zhan ZP; Wu QJ
    Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/β-catenin signaling pathway to suppress EMT in pancreatic tumor cells.
    Wu J; Li H; Shi M; Zhu Y; Ma Y; Zhong Y; Xiong C; Chen H; Peng C
    J Exp Clin Cancer Res; 2019 Aug; 38(1):348. PubMed ID: 31399111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator.
    Tsai YP; Chen HF; Chen SY; Cheng WC; Wang HW; Shen ZJ; Song C; Teng SC; He C; Wu KJ
    Genome Biol; 2014 Dec; 15(12):513. PubMed ID: 25517638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DUOX2-mediated production of reactive oxygen species induces epithelial mesenchymal transition in 5-fluorouracil resistant human colon cancer cells.
    Kang KA; Ryu YS; Piao MJ; Shilnikova K; Kang HK; Yi JM; Boulanger M; Paolillo R; Bossis G; Yoon SY; Kim SB; Hyun JW
    Redox Biol; 2018 Jul; 17():224-235. PubMed ID: 29715584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
    Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
    Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
    Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
    Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
    Bahar E; Kim JY; Kim HS; Yoon H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.